Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2021
Reporting Period: Quarter ended September 30, 2021
Context: The filing serves as a notification that the Company issued a press release announcing its financial results for the third quarter of 2021. The Company is designated as an emerging growth company.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain specific numerical comparisons or descriptions of material changes versus the prior comparable period. Investors must refer to the referenced press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release regarding Q3 2021 results but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K. The document includes a standard disclaimer that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 15, 2021) to obtain actual revenue, net loss, and cash position figures.
- Verify the Company's status as an emerging growth company and any associated accounting election impacts.
- Confirm the specific details of the Q3 2021 operational results which are not embedded in this summary text.
- Check for any forward-looking statements or updated guidance contained within the referenced press release.